The U.S. government plans to stockpile enough anthrax vaccine to treat 27 million people in case of a terrorist attack, with the supply to be spread out among several areas of the country. The purchase is expected to change the current orphan-drug type status of anthrax and make the purchases numerous enough to provide drug makers with an incentive to develop a modern version of the vaccine.

Related Summaries